Taipei, 11503, Taiwan
R&D expertise in developing novel cancer and infectious disease therapies. Lead product in development is OBI-822, a first-in-class active immunotherapy for metastatic breast cancer. The company is also the license holder for DIFICID in Taiwan and owns the commercial rights to the product, a novel antibiotic indicated for C. difficile-associated diarrhea.
Subsidiary of Orient Europharma (OEP). Focus on R&D and manufacturing of pharmaceuticals. Currently five new drug delivery technologies are being developed:
1. Multi-stages controlled release technology
2. Trans-dermal patches
3. Oral disintegrating tablets
4. Sustained release technology
Nangang Dist, Taipei 115,
New drug development in analgesics, cold remedies, gastrointestinal drugs, urinary system drugs, skin disease remedies. Also cosmeceuticals and nutritional products. Lead product is kidney drug Nephoxil, sold in the US as Auryxia under USFDA authority by Keryx Biopharmaceuticals Inc. Also sold in Japan.
Pharmaceutical technology and regulatory services, OEM/ODM manufacturer, CMO provider, and API manufacturer.
Has four plants:
Synthetic API plant
Sterile injection plant
Sterile synthetic API plant for oncology products
Sterile injection plant for oncology products
Services / technologies include:
Drug carriers, intermediates, API synthesis
Sterile API manufacturing
Aseptic filling manufacturing (powder, liquid and lyophilized powder)
Oral solid dosage drug development (Granules, tablets, capsules, sustained-release dosages, etc.)
Developer of repurposed drugs through modified drug delivery. Particular focus is on development of oral solid controlled-release technology, specifically on oral tablet/pellet controlled-release systems.
Received approval in May 2017 from the US FDA to market in the US a generic equivalent of the anti-psychotic drug Seroquel XR (quetiapine fumarate) at five different strengths.
Generic drug company, also OTC products, dietary supplements and medical devices (Bipolysorb, a bone filler).
Focus on drug delivery technologies, including peptide delivery systems, liposome technology, SR formulation, and orally disintegrating dosage technology.
API manufacturer, particularly oncology APIs. Is a specialist developer and producer of highly potent and cytotoxic compounds and injectables.